| Welcome to Palatin's Investor Relations Information Site. We are pleased to provide you with information regarding Palatin Technologies' financial highlights. For your convenience, we provide a library of press releases, events and webcasts, as well as prefiltered links to the EDGAR database. |
|
|
| |
Palatin at-a-Glance: |
 |
 |
 |
| |
| Palatin Technologies, Inc. (NYSE Amex:PTN) is a biopharmaceutical company dedicated to the development of peptide, peptide mimetic and small molecule agonist compounds with a focus on melanocortin and natriuretic peptide receptor systems. Palatin is developing products targeting melanocortin and natriuretic receptors, including products for treatment of sexual dysfunction, congestive heart failure, obesity and related metabolic syndrome. |
|
|
|
 |
|
 |
|
|
|
|
|
|
|
| |
| (as of 12/31/09) |
|
| NYSE Amex US symbol: |
PTN |
| Shares outstanding: |
|
| Common: |
96 million |
| Fully diluted: |
115 million |
| 52-wk price range: |
$0.06 - $0.48 |
| Market cap: |
$30 million |
| Employees: |
44 |
| Headquarters: |
Cranbury, NJ |
| Fiscal year end: |
June 30th |
| CEO: |
Dr. Carl Spana |
|
|
|
|
|
|
|
| |
|
|
Portions of this website may contain forward-looking statements concerning the future business, operating results and/or financial condition of Palatin Technologies, Inc. as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations and are subject to a number of uncertainties that could cause actual performance and results to differ materially from those anticipated by such forward-looking statements. For more information about these risks, please see the documents that the Company files from time to time with the Securities and Exchange Commission. Any forward-looking statements on this website are based on current expectations, and Palatin Technologies assumes no obligation to update them.
|
